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Introduction
Organochlorines (OCs) are a diverse group 
of persistent synthetic compounds that have 
been used as pesticides (mostly insecticides) 
and for various industrial and commercial 
applications.
OC insecticides were widely used in 
agriculture and pest control between the 
1940s and 1960s. Another group of OC 
compounds, polychlorinated biphenyls 
(PCBs), were historically used in numerous 
construction materials including plasticizers, 
adhesives, flame retardants, caulk, sealants, 
and paints, and in electrical equipment. These 
compounds resist degradation, bio accumulate 
in adipose tissue of humans and other 
tissues, and persist in the environment. 
Many countries banned their production in 
the 1970s and 1980s, citing public health 
concerns (Longnecker et al. 1997). Evidence 
suggests that some of these OC compounds 
may cause a variety of adverse health effects, 
including cancer. The International Agency 
for Research on Cancer (IARC) lists PCBs 
as carcinogenic to humans (Group 1) 
(Lauby-Secretan et al. 2013) although the 
assessment for the OC insecticides is less 
clear, with some specific insecticides listed 
as possible human carcinogens (Group 2B), 
and others listed as not classifiable (Group 3) 
(IARC 1991).
The  mechan i sms  by  wh i ch  OC 
compounds might influence cancer develop-
ment are not completely understood; 
however, many of the chemicals have been 
shown to have estrogenic, anti estrogenic, 
or anti androgenic properties (IARC 2012; 
Longnecker et al. 1997). Because of this, the 
impact of exposure to these compounds on 
risk of hormonal cancers, such as prostate 
cancer, is a concern. Several studies have 
reported associations between exposures 
to these compounds and prostate cancer 
among occupationally exposed populations 
(Prince et al. 2006; Purdue et al. 2007; 
Van Maele-Fabry and Willems 2004), but 
there is less information about associations 
with environmental exposures in the general 
population, which occur mainly from meat, 
fish, and dairy consumption (Kvalem et al. 
2009; Schecter et al. 2010). Associations of 
environmental OC exposures and prostate 
cancer have been evaluated in eight epide-
miologic studies (one ecologic study, one 
cross-sectional study, and six case–control 
studies) (Aronson et al. 2010; Hardell et al. 
2006; Kumar et al. 2010; Multigner et al. 
2010; Pavuk et al. 2004; Ritchie et al. 2003, 
2005; Sawada et al. 2010; Xu et al. 2010). A 
small hospital-based case–control study from 
the United States reported positive associa-
tions of PCB congener 180 and the chlordane 
metabolite oxychlordane with prostate cancer 
(Ritchie et al. 2003). Another hospital-based 
study from Sweden showed significant 
positive associations between PCB 153 and 
the chlordane constituent trans-chlordane 
and prostate cancer (Hardell et al. 2006). 
Two additional studies have shown statisti-
cally significant positive associations of other 
OC insecticides, including chlordecone, 
β-hexachloro cyclo hexane (HCH), and 
γ-HCH with prostate cancer (Kumar et al. 
2010; Multigner et al. 2010). Conversely, 
two studies, including the only study to use 
prospectively collected serum, have reported 
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Background: Organochlorine (OC) insecticides and polychlorinated biphenyls (PCBs) have been 
shown to have estrogenic, anti estrogenic, or anti androgenic properties; as a result, the impact of 
exposure to these compounds and risk of hormonal cancers, such as prostate cancer, is a concern.
oBjectives: We conducted a nested case–control study, using prospectively collected serum, to 
estimate associations between OC exposures and metastatic prostate cancer in a population-based 
cohort from Norway.
Methods: Sera from 150 cases and 314 controls matched on date of blood draw, age at blood 
draw, and region was used to determine concentrations of 11 OC pesticide metabolites and 34 PCB 
congeners. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for quartiles of lipid-
corrected metabolite levels were calculated using conditional logistic regression.
results: Metastatic prostate cancer was two times as likely among men with serum concentrations 
of oxychlordane in the highest quartile compared with those in the lowest quartile (OR = 2.03; 
95% CI: 1.03, 4.03; p-trend 0.05). Elevated but non significant ORs were estimated for the highest 
versus lowest quartile of heptachlor epoxide, HCB, and mirex, although these exposures were 
correlated with oxychlordane. Findings for specific PCB congeners showed a significant inverse 
association between natural log–transformed lipid-adjusted PCB 44 and metastatic prostate cancer 
(OR = 0.74; 95% CI: 0.56, 0.97; p-trend = 0.02).
conclusions: Our study highlights the importance of estimating associations with specific OC 
chemicals and suggests a possible role of OC insecticides and PCBs in the etiology of metastatic 
prostate cancer.
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inverse associations of prostate cancer with 
total PCBs overall, certain PCB congeners, 
and the OC insecticides β-HCH and γ-HCH 
(Aronson et al. 2010; Sawada et al. 2010).
Given these mixed results, we conducted 
a nested case–control study, using serum 
collected prior to diagnosis, to evaluate 
associations between environmental OC 
exposures and metastatic prostate cancer 
in the population-based Janus Serum Bank 
cohort of Norway.
Methods
Study population. The Janus Serum Bank 
cohort is a population-based research biobank 
dedicated to cancer studies. The cohort 
consists of almost 317,000 individuals with 
an average age at enrollment of 41 years. 
Participants were mainly recruited from 
county-based health surveys in the 1970s and 
1980s. Approximately 10% of the cohort 
members were recruited from Red Cross 
blood donors 18–65 years of age living in 
Oslo, the capital of Norway, with samples 
collected in the time period 1973–2004 
(Cancer Registry of Norway 2014). The 
Janus cohort was linked by national personal 
identification numbers to the Cancer Registry 
of Norway to identify new cases of prostate 
cancer. Concern about possible detection 
bias associated with prostate specific antigen 
(PSA) testing, which began in earnest 
around 1990 in Norway (Kvåle et al. 2007), 
led us to include only metastatic prostate 
cancer, which is less likely to be identified 
by screening. Thus, for the current nested 
case–control study, eligible cases consisted 
of all 184 incident metastatic prostate cancer 
cases with no history of cancer (except 
non melanoma skin cancer), who were diag-
nosed from enrollment through 31 December 
1999 and were diagnosed at least 2 years 
after serum collection. Metastasis and histo-
logic grade were charac terized according to 
the American Cancer Society’s Manual of 
Tumor Nomenclature and Coding (Percy et al. 
1968) or the International Classification of 
Diseases for Oncology (ICD-O) (World Health 
Organization 1976), depending on the year 
of diagnosis. Controls were randomly selected 
male members of the cohort who had no 
history of cancer (except for non melanoma 
skin cancer) at the time of their matched 
case’s diagnosis. The present study was part 
of a series of case–control studies relating 
serum OC concentrations to multiple 
cancer end points within the Janus cohort. 
Initially, at least 1 control was matched to 
each prostate cancer case. To increase statis-
tical power, controls initially selected for 
other end points also were included in the 
present analysis, allowing for up to 6 matched 
controls for some prostate cancer cases. A 
total of 389 eligible controls were identified 
for the prostate nested case–control study. 
Cases and controls were matched on date 
of blood draw (1-year strata), age at blood 
draw (2-year strata), and region (Finnmark, 
Oslo, Sogn og Fjordane, or Oppland). Sera 
from cases and their matched controls, 
including the augmented controls, were 
analyzed together in the same laboratory 
batch. Demographic data and other covari-
ates [including body mass index (BMI) and 
smoking habits] were obtained from baseline 
questionnaire data at the National Institute of 
Public Health, and census data were obtained 
from Statistics Norway (Langseth et al. 2010). 
This project was approved by the regional 
committees for medical and health research 
ethics, and all subjects provided consent prior 
to the study.
Laboratory analyses. Concentrations 
of 11 OC pesticides or their metabolites 
[β-HCH, γ-HCH, dieldrin, hexachloro-
benzene (HCB), mirex, o,p´-dichloro-
d i p h e n y l  t r i c h l o r o  e t h a n e  ( D D T ) , 
p,p´-dichloro diphenyl dichloro ethylene 
(DDE), p,p´-DDT, heptachlor epoxide, 
oxychlordane, and trans-nonachlor], 34 PCB 
congeners (PCBs 18, 28, 44, 49, 52, 66, 74, 
87, 99, 101, 118, 128, 138, 146, 149, 151, 
153, 156, 157, 167, 170, 172, 177, 178, 180, 
183, 187, 189, 194, 195, 196, 201, 206, and 
209), and lipid levels were measured at the 
Centers for Disease Control and Prevention, 
National Center for Environmental Health, 
in 0.8 mL of serum per participant available 
for the study. Measurements, methods, and 
quality control (QC) procedures for the larger 
study of OCs in relation to multiple cancer 
sites within the Janus cohort have been previ-
ously described in detail (Engel et al. 2007; 
Purdue et al. 2009). Briefly, serum samples 
were first spiked with isotopically labeled 
internal standards and then purified via auto-
mated accelerated solvent extraction and high-
resolution gel permeation chromatography on 
a high-performance liquid chromatograph. 
Concentrated extracts were analyzed by gas 
chromatography/high-resolution mass spec-
trometry. Selected PCB congeners and OC 
pesticides in each sample were quantified 
from 13C isotope dilution continuing cali-
bration plots, which automatically corrected 
for extraction efficiency. Values below the 
instrumental limits of detection (LOD) were 
imputed using a parametric model–based 
estimation procedure (Lubin et al. 2004). 
Using measure ments among controls for a 
target analyte, we used maximum-likelihood 
methods to estimate parameters for the log-
normal distribution. For each measurement 
< LOD, we randomly sampled a value from 
the appropriate log-normal distribution as the 
imputed value. As a QC check for possible 
errors in measurement due to interfering 
compounds, the ratio of 35Cl to 37Cl was 
calculated for each analyte and compared with 
the expected ratio for that analyte. Analyte 
measurements with observed ion ratios (IRs) 
greater than ± 20% of the expected IR were 
flagged as being out of tolerance and were 
recoded based on their proximity to the LOD: 
Flagged values ≤ 10 times the instrumental 
LOD were treated as if they were < LOD 
and imputed as described above, whereas 
flagged values > 10 times the instrumental 
LOD were recoded as missing data. Analytes 
with measurements either below the LOD or 
flagged as out of tolerance in at least half of 
the subjects (PCBs 87, 149, and 151) were 
also excluded from further analysis. Total 
lipid concentration was calculated for each 
subject using measurements of total choles-
terol and triglycerides. Masked QC samples, 
including single samples from a large pool and 
pairs of replicate samples, were inter spersed 
among study samples to assess intra batch and 
inter batch variability. The median intra batch 
coefficient of variation (CV) was 6 (range, 
3–16) and the median inter batch CV was 37 
(range, 17–165).
The serum samples from 29 cases were 
not successfully analyzed, and data were 
excluded for 5 cases from laboratory batches 
with aberrant measurements for both QC and 
subject samples, leaving 150 cases of prostate 
cancer for analysis. Serum samples from 
56 controls were not successfully analyzed, 
and data from 19 controls in the same 
aberrant batches as their 5 matched cases were 
excluded, leaving 314 controls for analysis.
Statistical analysis. Lipid-corrected serum 
concentrations were modeled continuously 
and natural log–transformed. They were 
also categorized into quartiles based on the 
distributions of each analyte among controls, 
with the lowest quartile used as the refer-
ence category in analyses. We used condi-
tional logistic regression matched on date of 
blood draw, age at blood draw, and region 
to calculate odds ratios (ORs) and 95% 
confidence intervals (95% CIs), and used the 
MIANALYZE procedure in SAS, version 
9.2 (SAS Institute Inc., Cary, NC, USA), to 
obtain the appropriate variance for imputed 
data. Analyses were conducted for individual 
analytes, total chlordane/heptachlor–related 
compounds (sum of heptachlor epoxide, 
oxychlordane, and trans-nonachlor), and total 
PCBs. In addition, experimental evidence 
suggests that some PCBs may exert estrogenic 
and possibly anti androgenic effects and induce 
cytochrome p450 activity (McFarland and 
Clarke 1989; Wolff et al. 1997). Thus, we also 
considered a priori groupings of PCB conge-
ners based on previously suggested groupings 
(low chlorinated: PCBs 11, 18, 28, 44, 49, 
52, 66, and 74; moderately chlorinated: PCBs 
99, 105, 110, 118, 128, 138, 146, 153, 156, 
157, 167, 170, 172, 177, 178, 180, 183, 187, 
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and 189; highly chlorinated: PCBs 194, 195, 
196, 201, 206, and 209; Wolff 1A: PCBs 
44, 49, and 52; Wolff 1B: PCBs 177, 187, 
and 201; Wolff 2A: PCBs 66, 74, 105, 118, 
156, and 167; Wolff 2B: PCBs 128, 138, and 
170; Wolff 3: PCBs 99, 153, 180, 183, and 
196). We also explored potential non linearity 
effects using 5-knot regression splines (piece-
wise polynomials). Likelihood ratio tests 
comparing the linear and spline models 
showed no improvement in model fit for the 
non linear model (data not shown), suggesting 
that the linear model, using the above defined 
quartiles, adequately fit the data. Separate 
analyses were conducted by grade of prostate 
cancer (moderately differentiated and poorly 
differentiated), time from blood draw to diag-
nosis (median: < 20 and ≥ 20 years), age at 
blood draw (median: ≤ 44 and > 44 years), 
BMI (< 25 kg/m2 and 25–29 kg/m2), as 
well as with additional adjustment for BMI 
(< 25 kg/m2, 25–29 kg/m2, ≥ 30 kg/m2) and 
smoking (never, former, current, missing). 
Likelihood ratio tests comparing models 
with and without the inter action term were 
used to formally assess differences between 
strata (p-interaction). Sensitivity analyses, 
excluding cases diagnosed after 1990 (when 
PSA testing began in earnest in Norway) and 
their matched controls, were also performed 
to assess the impact of detection bias. Tests 
for trend used the midpoint value of each 
exposure category treated as a continuous 
variable in regression models. All tests were 
two-sided and conducted at the α = 0.05 level.
Results
The mean age at enrollment for prostate cancer 
cases was slightly higher (43.8 years) compared 
with controls (42.0 years) (Table 1). Year 
of enrollment, BMI, and cigarette smoking 
status were comparable between cases and 
controls. The mean age at diagnosis for cases 
was 63.1 years and, as expected for metastatic 
cancer, most of the tumors were moderately or 
poorly differentiated. Median concentrations 
and ranges of each analyte (including imputed 
values for measurements below the LOD) in 
cases and controls, as well as intra batch and 
inter batch CVs and the percentage of measure-
ments below the LOD of all OCs in the Janus 
prostate study, are presented in Supplemental 
Material, Table S1.
Table 2 shows the association between 
OC insecticide metabolites and risk of meta-
static prostate cancer. Metastatic prostate 
cancer was two times as likely to occur 
among men with serum concentrations of 
oxychlordane in the highest quartile compared 
with those in the lowest quartile [OR for 
quartile 4 (Q4) vs. quartile 1 (Q1) = 2.03, 
95% CI: 1.03, 4.03; p-trend 0.05]. A similar 
association was estimated for hepta chlor 
epoxide when comparing the highest quartile 
with the lowest quartile, although this was 
not statistically significant (OR for Q4 vs. 
Q1 = 2.01, 95% CI: 0.98, 4.10). Elevated 
but non significant ORs were also estimated 
for the highest versus lowest quartiles of 
HCB and mirex. Heptachlor epoxide, HCB, 
and mirex were moderately correlated with 
oxychlordane [Spearman r = 0.55, r = 0.43 
and r = 0.49, respectively (see Supplemental 
Material, Table S2)], suggesting that the 
results for these analytes may not be indepen-
dent. However, mutually adjusted ORs based 
on models that included oxychlordane, hepta-
chlor epoxide, HCB, and mirex were unstable 
due to multi collinearity (data not shown). 
The entire Spearman correlation matrix for 
pesticides measured in Janus is presented in 
Supplemental Material, Table S2.
Table 3 shows the association between 
selected PCB congeners and PCB groupings 
and metastatic prostate cancer in the Janus 
study. Associations for the remaining PCB 
congeners are presented in Supplemental 
Material, Table S3. There was a significant 
inverse association between natural log–
transformed lipid-adjusted PCB 44 and risk 
of metastatic prostate cancer (OR = 0.74, 
95% CI: 0.56, 0.97; p-trend = 0.02; Table 3). 
An inverse association was also estimated for 
Wolff grouping 1A (p-trend = 0.03); there 
Table 1. Characteristics of prostate cases and controls in the Janus cohort.
Characteristic Cases (n = 150) Controls (n = 314)
Age at enrollment (mean ± SD) 43.8 ± 3.8 42.0 ± 6.2
Year of enrollment/collection [n (%)]
1972–1974 78 (52.0) 171 (54.5)
1975–1978 72 (48.0) 143 (45.5)
Body mass index [kg/m2; n (%)]
< 25 83 (55.3) 169 (53.8)
25–29 60 (40.0) 130 (41.4)
≥ 30 7 (4.7) 15 (4.8)
Cigarette smoking status [n (%)]
Never 26 (17.3) 58 (18.5)
Former 36 (24.0) 63 (20.1)
Current 73 (48.7) 163 (51.9)
Missing 15 (10.0) 30 (9.6)
Age at diagnosis (mean ± SD) 63.1 ± 5.3 —
Years from blood draw to diagnosis (mean ± SD) 17.8 ± 6.7 20.3 ± 4.9a
Tumor grade [n (%)]
Well differentiated 5 (3.3) —
Moderately differentiated 66 (44.0) —
Poorly differentiated 48 (32.0) —
Unknown 31 (20.7) —
aDefined as time from blood draw to matched case’s diagnosis date. 
Table 2. Association between organochlorine insecticides and risk of metastatic prostate cancer in the Janus cohort.
Metabolite
Continuous Q1 Q2 vs. Q1 Q3 vs. Q1 Q4 vs. Q1
p-TrendcORa,b (95% CI) Ca/Co Ca/Co ORb (95% CI) Ca/Co ORb (95% CI) Ca/Co ORb (95% CI)
Chlordane 1.09 (0.96, 1.24) 31/77 33/76 1.01 (0.52, 1.94) 44/81 1.39 (0.73, 2.62) 42/80 1.65 (0.82, 3.34) 0.13
Oxychlordane 1.26 (0.97, 1.64) 30/79 36/78 1.35 (0.70, 2.59) 37/79 1.34 (0.70, 2.55) 46/78 2.03 (1.03, 4.03) 0.05
trans-Nonachlor 1.29 (0.80, 2.08) 39/79 31/78 0.79 (0.43, 1.44) 35/79 0.89 (0.49, 1.63) 45/78 1.38 (0.73, 2.61) 0.19
Heptachlor epoxide 1.08 (0.82, 1.42) 32/78 33/79 1.01 (0.50, 2.02) 32/78 1.19 (0.60, 2.36) 52/79 2.01 (0.98, 4.10) 0.05
DDT 0.98 (0.88, 1.10) 34/79 36/78 0.94 (0.50, 1.78) 43/79 1.07 (0.59, 1.94) 37/78 0.97 (0.50, 1.88) 0.99
p,p’-DDT 0.97 (0.69, 1.38) 39/79 35/78 0.86 (0.46, 1.60) 33/79 0.76 (0.39, 1.47) 43/78 1.01 (0.52, 1.99) 0.75
p,p’-DDE 0.96 (0.72, 1.29) 35/79 32/78 0.80 (0.42, 1.51) 47/79 1.23 (0.69, 2.21) 36/78 0.90 (0.47, 1.73) 0.99
o,p’-DDT 0.96 (0.71, 1.28) 42/79 34/78 0.75 (0.41, 1.38) 27/79 0.62 (0.33, 1.19) 47/78 0.99 (0.50, 1.97) 0.58
Hexachlorobenzene 1.21 (0.75, 1.97) 29/79 49/78 1.70 (0.90, 3.22) 34/79 1.35 (0.62, 2.93) 38/78 2.03 (0.86, 4.84) 0.22
γ-Hexachlorocyclohexane 1.01 (0.81, 1.26) 41/79 33/78 0.79 (0.42, 1.47) 31/79 0.80 (0.41, 1.56) 45/78 1.10 (0.57, 2.12) 0.67
β-Hexachlorocyclohexane 1.19 (0.72, 1.95) 34/78 37/79 1.05 (0.56, 1.97) 29/79 0.75 (0.38, 1.50) 50/78 1.44 (0.71, 2.94) 0.29
Dieldrin 1.07 (0.87, 1.31) 32/78 37/77 1.14 (0.61, 2.15) 30/79 0.92 (0.46, 1.84) 50/80 1.42 (0.73, 2.77) 0.29
Mirex 1.26 (0.96, 1.65) 36/78 35/79 1.01 (0.55, 1.86) 34/79 0.94 (0.50, 1.77) 44/78 1.73 (0.90, 3.31) 0.07
Abbreviations: Ca/Co, cases/controls; DDE, dichlorodiphenyldichloroethylene; DDT, dichlorodiphenyltrichloroethane; OR, odds ratio; Q, quartile.
aPer unit increase in natural log–transformed ng/g lipid. bAdjusted for county, age at collection, and date at collection. cTrend of median values across quartiles.
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were no other statistically significant trends 
between any PCB congener or PCB grouping 
and metastatic prostate cancer (Table 3; see 
also Supplemental Material, Table S3).
Separate analyses conducted by grade 
of prostate cancer, time from blood draw 
to diagnosis, age at blood draw, and BMI 
showed no significant interactions and are 
therefore not shown. Additional adjustment 
for BMI and for smoking had only negligible 
effect on the observed OC–disease asso-
ciations and are therefore also not shown. 
Sensitivity analyses, excluding cases diagnosed 
after 1990 (n = 40), also produced minimal 
differences in the observed associations (data 
not shown).
Discussion
In this analysis, we estimated a significant 
positive association between metastatic 
prostate cancer and prediagnostic serum 
concentrations of the chlordane metabolite 
oxychlordane. Elevated, but non statistically 
significant, associations were also estimated 
for the chlordane/heptachlor-related metabo-
lite heptachlor epoxide and two other OC 
insecticides, HCB and mirex. Conversely, 
there were largely null associations for PCB 
congeners and PCB groupings with the 
exception of PCB 44, which was associated 
with a significant inverse risk of metastatic 
prostate cancer. These data highlight the 
importance of looking at specific OC chemi-
cals in evaluating risk and suggest a possible 
role of OC insecticides and PCBs in the 
etiology of metastatic prostate cancer.
Chlordane and heptachlor are structurally 
related OC insecticides that have been consid-
ered together in toxicity and carcino genicity 
evaluations because the technical-grade 
product of each contained about 10–20% 
of the other compound (IARC 2001). Their 
use has currently been banned or severely 
restricted in many countries; however, they 
are environmentally persistent. IARC lists both 
of these compounds as possibly carcinogenic 
to humans (Group 2B) owing to their ability 
to induce DNA damage and generate reactive 
oxygen species in experimental animal models 
(IARC 2001). These mechanisms, as well as 
postulated estrogenic or anti androgenic activity 
(Diamanti-Kandarakis et al. 2009), could 
play a role in prostate carcinogenesis. In the 
present study, metastatic prostate cancer was 
positively associated with the chlordane and 
heptachlor serum metabolites oxychlordane 
and heptachlor epoxide, particularly for the 
highest versus lowest quartiles of exposure. 
Elevated but non significant ORs were also esti-
mated for the highest versus lowest quartiles 
of HCB and mirex. Because serum concen-
trations of oxychlordane, heptachlor epoxide, 
HCB, and mirex are moderately correlated, it 
is difficult to estimate independent effects of 
these metabo lites, although these results do 
suggest that some or all of these agents may 
be involved. Other studies of circulating OCs 
and prostate cancer were more likely to show 
positive associations between chlordane or 
chlordane metabolites (Hardell et al. 2006; 
Ritchie et al. 2003) and prostate cancer, but 
further data are needed to prove whether this 
insecticide or its metabolites are etiologically 
important. It is also possible that our findings 
might be due to chance given the large number 
of comparisons considered.
Previous studies have shown associations 
between PCB 180 and PCB 153 and prostate 
cancer (Hardell et al. 2006; Ritchie et al. 
2003). These two congeners were measured 
with good accuracy and were also present in 
the highest concentrations in our study (see 
Supplemental Material, Table S1); however, 
they were not associated with metastatic 
prostate cancer in our study population. 
Results were null for all other congeners, 
with the exception of an inverse association 
between PCB 44 and metastatic prostate 
cancer. Two other studies have also reported 
inverse associations between specific PCB 
congeners and prostate cancer (Aronson et al. 
2010; Sawada et al. 2010), including the only 
other study that used prospectively collected 
samples (Sawada et al. 2010). Although it 
is unexpected that PCBs might be protec-
tive for prostate cancer, it is possible that the 
inverse associations could be reflective of real 
hormonal perturbations associated with PCB 
exposure that might also decrease prostate 
cancer development. Thus, the observed 
inverse association we, and others, have 
observed deserves further attention.
Few studies have looked at OCs in 
relation to more aggressive or lethal forms of 
prostate cancer. Sawada et al. (2010) found 
no association between serum OC insecticide 
concentrations and advanced prostate cancer, 
but they found an inverse association between 
total PCB concentrations and advanced 
prostate cancer. Conversely, Multigner et al. 
(2010) estimated stronger associations of 
serum concentrations of the OC insecticide 
chlordecone with highly aggressive forms of 
prostate cancer compared with less aggressive 
forms. In the occupational setting, a signifi-
cant association between exposure to the 
OC insecticide aldrin and aggressive prostate 
Table 3. Association between select PCB congeners and PCB groupings and risk of metastatic prostate cancer in the Janus study.
Metabolite
Continuous Q1 Q2 vs. Q1 Q3 vs. Q1 Q4 vs. Q1
p-TrendcORa,b (95% CI) Ca/Co Ca/Co ORb (95% CI) Ca/Co ORb (95% CI) Ca/Co ORb (95% CI)
Selected PCB congenerd
44 0.74 (0.56, 0.97) 48/79 38/78 0.74 (0.41, 1.33) 39/79 0.67 (0.35, 1.28) 25/78 0.39 (0.17, 0.86) 0.02
101 0.79 (0.57, 1.09) 48/79 28/78 0.52 (0.29, 0.95) 45/79 0.84 (0.47, 1.49) 29/78 0.51 (0.25, 1.03) 0.16
153 0.92 (0.59, 1.43) 35/79 39/78 1.01 (0.57, 1.78) 42/79 1.04 (0.58, 1.85) 34/78 0.83 (0.44, 1.56) 0.56
180 0.64 (0.36, 1.13) 31/77 43/79 1.19 (0.66, 2.17) 48/80 1.38 (0.75, 2.54) 28/78 0.71 (0.36, 1.38) 0.25
189 0.90 (0.73, 1.12) 47/78 41/79 0.93 (0.43, 2.00) 33/79 0.72 (0.34, 1.54) 29/78 0.64 (0.30, 1.37) 0.18
Total PCBse 0.99 (0.98, 1.01) 38/78 38/79 0.82 (0.46, 1.45) 34/77 0.82 (0.45, 1.50) 40/80 0.92 (0.50, 1.68) 0.88
Degree of chlorinationf
Low 0.95 (0.89, 1.01) 44/78 37/79 0.58 (0.31, 1.09) 34/78 0.58 (0.29, 1.17) 35/79 0.59 (0.26, 1.32) 0.44
Moderate 1.00 (0.98, 1.02) 33/76 38/80 0.92 (0.51, 1.65) 44/80 1.22 (0.68, 2.21) 35/78 0.94 (0.51, 1.73) 0.99
High 0.99 (0.91, 1.08) 38/78 35/79 1.00 (0.57, 1.77) 45/79 1.18 (0.67, 2.06) 32/78 0.89 (0.48, 1.64) 0.73
Wolff groupg
1 0.95 (0.88, 1.02) 42/76 39/81 0.88 (0.49, 1.56) 41/78 0.97 (0.54, 1.72) 28/79 0.63 (0.32, 1.23) 0.19
1A 0.91 (0.81, 1.01) 48/78 36/79 0.67 (0.37, 1.19) 40/79 0.62 (0.33, 1.18) 26/78 0.39 (0.18, 0.85) 0.03
1B 0.97 (0.86, 1.10) 38/78 38/79 0.92 (0.52, 1.63) 39/78 1.06 (0.60, 1.90) 35/79 0.88 (0.48, 1.62) 0.77
2 0.99 (0.93, 1.05) 38/77 35/80 0.80 (0.44, 1.43) 41/78 1.09 (0.62, 1.91) 36/79 0.85 (0.45, 1.60) 0.85
2A 0.99 (0.90, 1.09) 40/78 38/78 0.84 (0.47, 1.50) 35/80 0.89 (0.50, 1.60) 37/78 0.91 (0.48, 1.72) 0.88
2B 0.98 (0.87, 1.10) 33/78 42/78 1.14 (0.64, 2.03) 43/79 1.23 (0.69, 2.19) 32/79 0.85 (0.46, 1.60) 0.60
3 0.96 (0.87, 1.06) 34/78 40/79 1.06 (0.60, 1.86) 43/79 1.13 (0.63, 2.05) 33/78 0.84 (0.45, 1.57) 0.57
Abbreviations: Ca/Co, cases/controls; OR, odds ratio; PCB, polychlorinated biphenyl; Q, quartile. 
aPer unit increase in natural log–transformed ng/g lipid. bAdjusted for county, age at collection, and date at collection. cTrend of median values across quartiles. dEstimates for the 
remaining PCBs are provided in Supplemental Material, Table S3. eSum of all congeners included in the analysis. fLow: PCBs 11, 18, 28, 44, 49, 52, 66, and 74; moderate: PCBs 99, 105, 
110, 118, 128, 138, 146, 153, 156, 157, 167, 170, 172, 177, 178, 180, 183, 187, and 189; high: PCBs 194, 195, 196, 201, 206, and 209. gWolff 1A: PCBs 44, 49, and 52; Wolff 1B: PCBs 177, 187, and 
201; Wolff 2A: PCBs 66, 74, 105, 118, 156, and 167; Wolff 2B: PCBs 128, 138, and 170; Wolff 3: PCBs 99, 153, 180, 183, and 196.
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cancer was observed in U.S. farmers, while 
there was no association with non aggressive 
disease (Koutros et al. 2013). It should be 
noted, however, that each of the above studies 
used different methods to characterize more 
advanced/aggressive forms of prostate cancer, 
making comparisons of results across studies 
more difficult to interpret. Because prostate 
cancer is present in a large proportion of 
older men as an indolent disease, exposures 
positively associated with metastatic, but 
not indolent, prostate cancer might suggest 
factors involved in the progression of early 
stage disease to the more readily detectable 
aggressive form. Future work on the mecha-
nisms by which OC insecticides might impact 
the development of aggressive or lethal forms 
of prostate cancer would be valuable.
Our study is one of the largest to evaluate 
environmental OC serum concentrations and 
risk of prostate cancer and only the second 
to use prospectively collected samples. Also, 
samples were collected in the 1970s and 
likely reflect peak or near-peak body burden 
of these compounds among the general 
population. In fact, concentrations of most 
OC metabolites were generally higher in the 
Janus cohort compared with more contem-
porary studies of prostate cancer cases and 
controls from Japan, Sweden, Canada, and 
the United States (Aronson et al. 2010; 
Ritchie et al. 2003; Sawada et al. 2010; Xu 
et al. 2010). Identification of metastatic 
disease also allowed us to consider the more 
lethal form of prostate cancer and to reduce 
the possibility of detection bias due to PSA 
screening because metastatic cancer is usually 
not detected by screening and may have a 
different etiology than more slow growing, 
or non aggressive forms of the disease 
(Giovannucci et al. 2007). Nonetheless, 
some limitations must be acknowledged. QC 
results showed that measurement precision 
for analytes was variable. Quartile analyses 
resulted in modest numbers of cases in some 
categories, limiting the power to detect asso-
ciations if they exist, in particular for strati-
fied analyses. Because this study, and other 
prospective studies, have shown modest 
estimated effects for the associa tion between 
OC compounds and advanced forms of 
prostate cancer, future studies should try 
to improve on the power to detect modest 
associations (in the range of 1.5–2.0) with 
more aggressive forms of the disease. Also, 
the high degree of correlation between many 
of these compounds limited our ability to 
examine independent effects. The power to 
examine interactions between OC metabo-
lites and several factors was limited and thus 
provided little additional insight into the 
possible modification of associations between 
OC exposures and metastatic prostate 
cancer. Given the large number of measured 
compounds and general borderline signifi-
cance level of observed findings, correction 
for multiple comparisons would have elimi-
nated all observed effects, so we cannot rule 
out the possibility of false-positive associa-
tions. We also cannot rule out the possibility 
of false-negative associations, which may be a 
consequence of exposure misclassification.
Conclusions
Metastatic prostate cancer was positively asso-
ciated with prediagnostic serum concentrations 
of the OC insecticide metabolites oxychlor-
dane, heptachlor epoxide, HCB, and mirex. 
Findings for specific PCB congeners or group-
ings were largely null, although there was a 
significant inverse association with PCB 44. 
These results suggest that certain OC insecti-
cides and PCB congeners may contribute to 
metastatic prostate cancer. Additional prospec-
tive epidemiologic studies with the ability to 
look at the more aggressive forms of prostate 
cancer are needed to identify etiologic factors 
associated with the more lethal form of this 
disease. These studies should consider whether 
individual OC compounds appear to influence 
disease, as associations appear to be chemical 
specific, and should consider both positive 
and inverse associations suggested by this and 
other studies.
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